Hypothesis

Sleep‑dependent glymphatic flux does not only clear neuronal waste; it also circulates a soluble factor that targets senescent stromal cells in the endometrium, promoting their clearance or suppressing their SASP. When sleep is fragmented, this nocturnal endocrine‑like signal diminishes, allowing CDC42‑deficient stromal cells to accumulate and sabotage decidualization.

Mechanistic Basis

Recent work shows that endometrial stromal senescence in recurrent implantation failure is driven by loss of CDC42 activity, leading to p16/p21 elevation and a pro‑inflammatory SASP that blocks decidualization【2】【3】. The glymphatic system, most active during slow‑wave sleep, exchanges cerebrospinal fluid with interstitial fluid and can release soluble peptides into the circulation【4】. We propose that a sleep‑regulated peptide—perhaps a fragment of clusterin or apolipoprotein E—binds to senescent stromal cells, either enhancing their susceptibility to natural killer‑cell clearance or inhibiting NF‑κB‑driven SASP transcription. In sleep‑disrupted conditions, reduced glymphatic efflux lowers circulating levels of this peptide, tipping the balance toward stromal senescence persistence.

Testable Predictions

1. Biomarker correlation – Women with objectively measured reduced slow‑wave sleep (actigraphy/EEG) will have higher plasma concentrations of SASP cytokines (IL‑6, IL‑8, MCP‑1) and lower levels of the putative glymphatic‑derived peptide compared with age‑matched controls with normal sleep.
2. Intervention experiment – In a murine model of endometrial stromal senescence (induced by stromal‑specific Cdc42 knockout), administering a glymphatic enhancer (e.g., low‑dose acetazolamide to increase CSF flow) during the rest phase will decrease endometrial p16⁺ stromal cells and improve implantation rates relative to vehicle.
3. Cell‑culture assay – Treating primary human endometrial stromal cells made senescent by CDC42 siRNA with cerebrospinal fluid harvested from sleeping versus sleep‑deprived donors will differentially affect SASP secretion; CSF from slept donors will reduce IL‑6/IL‑8 release and increase senescent cell apoptosis.
4. Genetic link – Polymorphisms in genes governing glymphatic transport (e.g., Aquaporin‑4) will associate with recurrent implantation failure risk in genome‑wide association studies, independent of oocyte quality markers.

Falsifiability

If plasma SASP levels do not rise with reduced slow‑wave sleep, or if enhancing glymphatic flow fails to lower endometrial stromal senescence in the Cdc42‑deficient mouse model, the hypothesis would be refuted. Likewise, if CSF from slept and sleep‑deprived donors shows no differential effect on stromal SASP in vitro, the proposed soluble factor would lack support.